GRI Bio, Inc. (GRI) stock
GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.27−0.08 (-5.95%)
Close on Nov 18, 2026Market cap $2.78MP/E –Yield –
GRI Bio operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
GRI Bio's operating cash flow for the twelve months ending Jun 30, 2026 was -$10.42M. For fiscal 2025 it was -$10.19M. The highest annual figure on record is -$1.09M in fiscal 2022.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$10.19M | – |
| FY2024 | Dec 31, 2024 | -$8.61M | – |
| FY2023 | Dec 31, 2023 | -$8.99M | – |
| FY2022 | Dec 31, 2022 | -$1.09M | – |
| FY2021 | Dec 31, 2021 | -$8.31M | – |
| FY2020 | Dec 31, 2020 | -$3.71M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.45M | – |
| Q1 FY2026 | Mar 31, 2026 | -$3.69M | – |
| Q4 FY2025 | Dec 31, 2025 | -$2.97M | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.31M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.74M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.00M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.27M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.14M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.20M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.56M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.31M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.54M | -170.8% |
| Q1 FY2023 | Mar 31, 2023 | -$579.00K | – |
| Q4 FY2022 | Dec 31, 2022 | -$844.00K | – |
| Q3 FY2022 | Sep 30, 2022 | -$125.00K | – |
| Q2 FY2022 | Jun 30, 2022 | $2.17M | – |
| Q1 FY2022 | Mar 31, 2022 | -$2.29M | – |
| Q4 FY2021 | Dec 31, 2021 | -$1.58M | – |
| Q3 FY2021 | Sep 30, 2021 | -$1.29M | – |
| Q2 FY2021 | Jun 30, 2021 | -$2.49M | – |
| Q1 FY2021 | Mar 31, 2021 | -$2.95M | – |
| Q4 FY2020 | Dec 31, 2020 | -$808.00K | – |
| Q3 FY2020 | Sep 30, 2020 | -$1.06M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.07M | – |
| Q1 FY2020 | Mar 31, 2020 | -$766.00K | – |
See a number that looks wrong?